22 Marzo 2019

FDA Halts Enrollment on Venetoclax Myeloma Trials

March 19, 2019 – The FDA has placed a partial clinical hold on all clinical trials examining venetoclax in multiple myeloma, halting enrollment of new patients on the studies, according to AbbVie, which jointly develops the BCL-2 inhibitor with Genentech (Roche). AbbVie reported in a press release that the partial hold is based on safety data from the ongoing phase III BELLINI trial (M14-031; NCT02755597). The results showed a higher rate of patient deaths … (leggi tutto)